"Broad spectrum" antidepressants: is more better for the treatment of depression?
about
The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization propertiesAnimal models of depression in dopamine, serotonin, and norepinephrine transporter knockout mice: prominent effects of dopamine transporter deletionsTriple reuptake inhibitors: the next generation of antidepressantsTriple uptake inhibitors: therapeutic potential in depression and beyondEmerging targets for antidepressant therapiesDOV 216,303, a "triple" reuptake inhibitor: safety, tolerability, and pharmacokinetic profileSKF83959 is a novel triple reuptake inhibitor that elicits anti-depressant activityTriple Reuptake Inhibitors: A Premise and PromisePreclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor.Advances in the treatment of depressionThe effects of dopaminergic/serotonergic reuptake inhibition on maternal behavior, maternal aggression, and oxytocin in the rat.Future prospects in depression researchThe novel trisubstituted pyran derivative D-142 has triple monoamine reuptake inhibitory activity and exerts potent antidepressant-like activity in rodents.Differential BDNF responses of triple versus dual reuptake inhibition in neuronal and astrocytoma cells as well as in rat hippocampus and prefrontal cortex.Computational models of neuronal biophysics and the characterization of potential neuropharmacological targets.Emerging treatments for depression.Structural exploration of (3S,6S)-6-benzhydryl-N-benzyltetrahydro-2H-pyran-3-amine analogues: identification of potent triple monoamine reuptake inhibitors as potential antidepressantsTriple reuptake inhibitors as potential next-generation antidepressants: a new hope?Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited.Triple monoamine uptake inhibitors.Triple reuptake inhibitors: a patent review (2006 - 2012).Addiction-related effects of DOV 216,303 and cocaine: A comparative study in the mouse.Enantiopurity determination of the enantiomers of the triple reuptake inhibitor indatraline.Monoamine reuptake inhibition and mood-enhancing potential of a specified oregano extract.Reciprocal effects of combined administration of serotonin, noradrenaline and dopamine reuptake inhibitors on serotonin and dopamine levels in the rat prefrontal cortex: the role of 5-HT1A receptors.The triple reuptake inhibitor DOV216,303 exhibits limited antidepressant-like properties in the differential reinforcement of low-rate 72-second responding assay, likely due to dopamine reuptake inhibition.Effect of chronic administration of ketamine on the mitochondrial respiratory chain activity caused by chronic mild stress.MS Binding Assays for the Three Monoamine Transporters Using the Triple Reuptake Inhibitor (1R,3S)-Indatraline as Native Marker.
P2860
Q24633511-B6A37F03-690A-43DA-9CDA-61CE33533686Q24651067-CB59F0A2-C844-44E6-BE44-A64710B63346Q24658248-387B6BE5-EEFE-4C36-87FE-3121F60A5E10Q28241732-43574703-D112-4F3B-A7BE-BF63465617B0Q28247614-9DFDBAC9-5C77-499C-A459-5AB129006743Q28293513-25DE9D6D-9327-4623-A1A0-3035B2425741Q28295413-0A2C874A-E430-443C-ADB2-356650E30A6BQ28972234-BEF0BCAF-6B2E-4F7B-9B05-E487B722222EQ33999301-9E76661F-456F-4204-9D9E-CAD4DDEF7309Q34496251-8BA7F742-9B24-4341-8C52-96A421760092Q35031118-85BB4644-7DDD-4CE7-8414-54F716E73061Q35236701-4B2C5EAB-09BF-46D9-A801-9DF781E11264Q35532003-29A0F739-6564-4653-8F6B-D4D0E7A90646Q36147115-87EB67F2-2E1C-4028-9DEB-BE27B6554445Q36576250-85726057-8935-4216-AF7B-CF7EA56E5E09Q36655168-32C6A2B7-EC26-490D-8AA3-34934E5EAB9FQ37071538-BF290C59-2962-4E22-A4E8-3C119DEF2FEDQ37158450-190827EA-ED1A-4F94-9CF7-30A4DA59593DQ37891098-04BA78E4-64A1-4D86-92F7-599A7F6E73B9Q38162938-7608FE7D-FFE5-49AF-A72D-F77DB7879111Q38167327-F135054E-5A78-446C-9946-2576AA61FA47Q39299851-238BF5B7-C0DE-429A-82E0-6015B9B4A436Q44134659-5B5C0F6C-79AA-460C-9892-575EE2178291Q44371464-EBD2FDAA-6228-40E3-B0E9-E964DB5FDE27Q46913603-4D7C5E1C-D483-48ED-BB2D-E967786D05A2Q48371652-8002EF3C-FFDF-446F-905A-47A909EFEBD1Q48955474-1DC821A2-8008-4955-A3AC-E851973C45B0Q53532774-9C710E86-6F3C-4B9E-89EA-71CA4569483E
P2860
"Broad spectrum" antidepressants: is more better for the treatment of depression?
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
"Broad spectrum" antidepressants: is more better for the treatment of depression?
@ast
"Broad spectrum" antidepressants: is more better for the treatment of depression?
@en
type
label
"Broad spectrum" antidepressants: is more better for the treatment of depression?
@ast
"Broad spectrum" antidepressants: is more better for the treatment of depression?
@en
prefLabel
"Broad spectrum" antidepressants: is more better for the treatment of depression?
@ast
"Broad spectrum" antidepressants: is more better for the treatment of depression?
@en
P2093
P1433
P1476
"Broad spectrum" antidepressants: is more better for the treatment of depression?
@en
P2093
Aaron Janowsky
Arnold S Lippa
Bernard Beer
Phil Skolnick
P304
P356
10.1016/J.LFS.2003.06.007
P407
P50
P577
2003-11-01T00:00:00Z